Search results for " Middle"

showing 10 items of 1097 documents

A multicentre case control study on complicated coeliac disease: two different patterns of natural history, two different prognoses

2014

Background: Coeliac disease is a common enteropathy characterized by an increased mortality mainly due to its complications. The natural history of complicated coeliac disease is characterised by two different types of course: patients with a new diagnosis of coeliac disease that do not improve despite a strict gluten-free diet (type A cases) and previously diagnosed coeliac patients that initially improved on a gluten-free diet but then relapsed despite a strict diet (type B cases). Our aim was to study the prognosis and survival of A and B cases. Methods: Clinical and laboratory data from coeliac patients who later developed complications (A and B cases) and sex- and age-matched coeliac p…

MaleComplicationsSettore MED/09 - Medicina InternaLymphomaSmallGastroenterologyCoeliac diseaseEnteropathy-Associated T-Cell LymphomaIntestine SmallMedicineCeliac diseaseEnteropathyTreatment FailureINTESTINAL T-CELL LYMPHOMAGastroenterologyGLUTEN FREE DIETGeneral Medicinecomplicated coeliac disease; natural history; prognosis;IleitisMiddle AgedPrognosisEnteritisIntestineNatural historyAdult; Aged; Carcinoma; Case-Control Studies; Celiac Disease; Collagenous Sprue; Disease Progression; Enteritis; Enteropathy-Associated T-Cell Lymphoma; Female; Humans; Ileitis; Intestinal Neoplasms; Intestine Small; Jejunal Diseases; Lymphoma B-Cell; Male; Middle Aged; Prognosis; Treatment Failure; Diet Gluten-Freenatural historyGluten-free dietDisease ProgressionEnteropathy-associated T-cell lymphomaFemaleprognosiResearch ArticleCollagenous SprueAdultmedicine.medical_specialtyLymphoma B-CellGlutensSettore MED/12 - GASTROENTEROLOGIAcomplicated coeliac diseasecomplications/drug therapy/mortality Myocytes; celiac diseaseNODiet Gluten-FreeInternal medicineIntestinal NeoplasmsHumanscomplications/drug therapy/mortalitySurvival rateCELIAC DISEASE; Complications; INTESTINAL T-CELL LYMPHOMA; prognosis; GLUTEN FREE DIETAgedcomplications/drug therapy/mortality; Myocytes; celiac diseaseMyocytesbusiness.industryCarcinomaB-CellCase-control studynutritional and metabolic diseasesJejunal DiseasesHepatologymedicine.diseasedigestive system diseasesDietEATLCase-Control StudiesGluten-FreeGluten freebusinessComplicationcoeliac disease
researchProduct

Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.

2008

The aim of this study was to compare the analgesic and adverse effects, doses, as well as cost of opioid drugs, supportive drug therapy and other analgesic drugs in patients treated with oral sustained-release morphine, transdermal fentanyl, and oral methadone.One hundred and eight cancer patients, no longer responsive to opioids for moderate pain, were selected to randomly receive initial daily doses of 60 mg of oral sustained-release morphine, 15 mg of oral methadone, or 0.6 mg (25 microg/h) of transdermal fentanyl. Oral morphine was used as breakthrough pain medication during opioid titration. Opioid doses, pain intensity, adverse effects, symptomatic drugs, were recorded at week interva…

MaleCost-Benefit AnalysisAdministration OralFentanylNeoplasmscancer pain opioidsProspective StudiesCancer painTransdermalIntractableAnalgesicsMorphineMiddle AgedPain IntractableAnalgesics OpioidFentanylNeuropsychology and Physiological PsychologyTreatment OutcomeNeurologyPatient SatisfactionAnesthesiaAdministrationFemaleDrugmedicine.drugOralAdultAdolescentAnalgesicPainOpioidAdministration CutaneousDrug Administration ScheduleDose-Response RelationshipmedicineHumansAdverse effectAgedDose-Response Relationship Drugbusiness.industryCostsCutaneousAnesthesiology and Pain MedicineOpioidCancer pain; Costs; Fentanyl; Methadone; Morphine; Administration Cutaneous; Administration Oral; Adolescent; Adult; Aged; Analgesia; Analgesics Opioid; Cost-Benefit Analysis; Dose-Response Relationship Drug; Drug Administration Schedule; Female; Fentanyl; Humans; Male; Methadone; Middle Aged; Morphine; Neoplasms; Pain Intractable; Patient Satisfaction; Prospective Studies; Quality of Life; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology; Neuropsychology and Physiological PsychologyMorphineQuality of LifeAnalgesiaCancer painbusinessMethadoneMethadoneEuropean journal of pain (London, England)
researchProduct

Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study

2019

Abstract Background Few data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis. Aims to describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription. Methods This multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. The primary endpoint was overall ustekinumab persistence, defined as the maintenance of therapy because of sustained clinical benefit for IBD. Results Seventy patients (64 Crohn’s disease…

MaleCrohn’s diseaseSettore MED/16 - REUMATOLOGIAPsoriaticCrohn's disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; Ustekinumab; Hepatology; GastroenterologyInflammatory bowel disease0302 clinical medicineClinical endpointCrohn's disease Psoriasis Psoriatic arthritis Ulcerative colitis UstekinumabCrohn's diseaseSettore MED/12 - GastroenterologiaGastroenterologyMiddle AgedUlcerative colitisCrohn's diseaseTreatment OutcomeItaly030220 oncology & carcinogenesisPsoriatic arthritis030211 gastroenterology & hepatologyFemaleUstekinumabmedicine.drugAdultmedicine.medical_specialty03 medical and health sciencesPsoriatic arthritisCrohn's disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; Ustekinumab; Adult; Aged; Arthritis Psoriatic; Dermatologic Agents; Female; Humans; Inflammatory Bowel Diseases; Italy; Logistic Models; Male; Middle Aged; Psoriasis; Retrospective Studies; Treatment Outcome; Ustekinumab; Young AdultYoung AdultInternal medicinePsoriasisUstekinumabmedicineHumansPsoriasisAgedRetrospective StudiesHepatologybusiness.industryArthritisArthritis Psoriaticmedicine.diseaseInflammatory Bowel Diseasesdigestive system diseasesCrohn’s disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; UstekinumabLogistic ModelsUlcerative colitisConcomitantDermatologic Agentsbusiness
researchProduct

Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension

2020

Several factors have been proposed to explain the high death rate of the coronavirus disease 2019 (COVID-19) outbreak, including hypertension and hypertension-related treatment with Renin Angiotensin System inhibitors. Also, age and multimorbidity might be confounders. No sufficient data are available to demonstrate their independent role. We designed a cross-sectional, observational, multicenter, nationwide survey in Italy to verify whether renin-angiotensin system inhibitors are related to COVID-19 severe outcomes. We analyzed information from Italian patients diagnosed with COVID-19, admitted in 26 hospitals. One thousand five hundred ninety-one charts (male, 64.1%; 66±0.4 years) were r…

MaleCross-sectional studyAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyRenin-Angiotensin System0302 clinical medicine80 and overMedicineodds ratioodds ratio.030212 general & internal medicineViralYoung adultSocieties MedicalAged 80 and overCOVID-19; hypertension; Italy; multimorbidity; odds ratio; Adolescent; Adult; Age Distribution; Age Factors; Aged; Aged 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Coronavirus Infections; Cross-Sectional Studies; Female; Humans; Hypertension; Italy; Male; Middle Aged; Multimorbidity; Pandemics; Pneumonia Viral; Prognosis; Renin-Angiotensin System; Survival Rate; Young Adult; Betacoronavirus; Societies MedicalMortality rateAge FactorsMiddle AgedPrognosisSurvival RateItalyCOVID-19; hypertension; Italy; multimorbidity; odds ratioFemaleCoronavirus InfectionsAdultmedicine.medical_specialtyhypertensionAdolescentmultimorbidityPneumonia ViralCOVID-19; Italy; hypertension; multimorbidity; odds ratio03 medical and health sciencesAngiotensin Receptor AntagonistsYoung AdultBetacoronavirusAge DistributionInternal medicineDiabetes mellitusMedicalInternal MedicineHumansSurvival ratePandemicsAgedbusiness.industrySARS-CoV-2COVID-19Odds ratioPneumoniamedicine.diseaseCross-Sectional StudiesHeart failureCOVID-19; Hypertension; Italy; Multimorbidity; Odds ratio; Adolescent; Adult; Age Distribution; Age Factors; Aged; Aged 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; COVID-19; Coronavirus Infections; Cross-Sectional Studies; Female; Humans; Hypertension; Italy; Male; Middle Aged; Multimorbidity; Pandemics; Pneumonia Viral; Prognosis; Renin-Angiotensin System; SARS-CoV-2; Survival Rate; Young Adult; Betacoronavirus; Societies MedicalbusinessSocietiesKidney disease
researchProduct

Pruritus characteristics in a large Italian cohort of psoriatic patients

2019

Background: Psoriasis (Ps) is a chronic systemic autoimmune disease associated with pruritus in 64–98% of patients. However, few modestly sized studies assess factors associated with psoriatic pruritus. Objective: To investigate factors associated with Ps pruritus intensity. Methods: Psoriasis patients 18 years or older seen in one of 155 centres in Italy between September 2005 and 2009 were identified from the Italian PsoCare registry. Patients without cutaneous psoriasis and those with missed information on pruritus were excluded. Results: We identified 10 802 patients, with a mean age 48.8 ± 14.3 years. Mild itch was present in 33.2% of patients, moderate in 34.4%, severe in 18.7% and ve…

MaleCross-sectional studySeverity of Illness IndexCohort Studies030207 dermatology & venereal diseases0302 clinical medicineRisk Factorseducation; itch; pruritus; psoriasis; pustular psoriasis; treatment; Adolescent; Adult; Cohort Studies; Cross-Sectional Studies; Educational Status; Facial Dermatoses; Female; Foot Dermatoses; Genitalia; Hand Dermatoses; Humans; Italy; Male; Middle Aged; Pruritus; Psoriasis; Registries; Risk Factors; Severity of Illness Index; Sex Factors; Young AdultEpidemiologyitchRegistriesYoung adultskin and connective tissue diseaseseducationtreatmentMiddle AgedSettore MED/33 - MALATTIE APPARATO LOCOMOTOREInfectious Diseasespustular psoriasisItaly030220 oncology & carcinogenesisCohortEducational StatusPRURITIS EPIDEMIOLOGYFemaleSettore MED/35 - MALATTIE CUTANEE E VENEREECohort studyAdultmedicine.medical_specialtyAdolescentPSORIASDermatologyHand DermatosesArticle03 medical and health sciencesYoung AdultPharmacotherapySex FactorsSettore MED/35PsoriasisSeverity of illnessmedicineHumansPsoriasisGenitaliaFoot Dermatosesbusiness.industryPruritusmedicine.diseaseDermatologyPruritusItch sensationCross-Sectional StudiesbusinessFacial Dermatoses
researchProduct

Delayed post-ischemic administration of CDP-choline increases EAAT2 association to lipid rafts and affords neuroprotection in experimental stroke

2007

Glutamate transport is the only mechanism for maintaining extracellular glutamate concentrations below excitotoxic levels. Among glutamate transporters, EAAT2 is responsible for up to 90% of all glutamate transport and has been reported to be associated to lipid rafts. In this context, we have recently shown that CDP-choline induces EAAT2 translocation to the membrane. Since CDP-choline preserves membrane stability by recovering levels of sphingomyelin, a glycosphingolipid present in lipid rafts, we have decided to investigate whether CDP-choline increases association of EAAT2 transporter to lipid rafts. Flotillin-1 was used as a marker of lipid rafts due to its known association to these m…

MaleCytidine Diphosphate CholineTime FactorsIschemiaGlutamic AcidContext (language use)PharmacologyBiologyCell FractionationNeuroprotectionlcsh:RC321-571chemistry.chemical_compoundMembrane MicrodomainsIschemiamedicineAnimalsCholineLipid raftlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryGlutamate transportersGlutamate receptorInfarction Middle Cerebral ArteryGlutamic acidmedicine.diseaseRats Inbred F344Ratscarbohydrates (lipids)Disease Models AnimalNeuroprotective AgentsExcitatory Amino Acid Transporter 2Gene Expression RegulationNeurologyBiochemistrychemistrylipids (amino acids peptides and proteins)GlutamateSphingomyelinNeurobiology of Disease
researchProduct

Subthalamic deep brain stimulation improves time perception in Parkinson's disease.

2004

Alterations in temporal estimation have been observed in Parkinson's disease (PD) and have been associated with dopaminergic dysfunction. To investigate whether deep brain stimulation might reverse these abnormalities in PD, patients treated with electrode implantation for subthalamic deep brain stimulation were required to reproduce time intervals in different experimental conditions (off deep brain stimulation/off therapy, on deep brain stimulation/off therapy, on therapy/off deep brain stimulation). Patients treated with deep brain stimulation in off deep brain stimulation/off therapy displayed the anomalous pattern of responses typically observed in PD. When subthalamic deep brain stimu…

MaleDeep brain stimulationParkinson's diseaseDeep brain stimulation; Memory; Parkinsons disease; Time perception;Parkinson's diseasemedicine.medical_treatmentCentral nervous systemElectric Stimulation TherapyNOmemoryParkinsons diseaseBasal gangliamedicineHumansAnalysis of Variance; Parkinson Disease; Humans; Electric Stimulation Therapy; Time Perception; Aged; Middle Aged; Subthalamus; Male; FemaleDeep transcranial magnetic stimulationPrefrontal cortexAgedAnalysis of VarianceSettore M-PSI/02 - Psicobiologia E Psicologia Fisiologicabusiness.industryGeneral NeuroscienceDopaminergicParkinson DiseaseTime perceptionMiddle Agedmedicine.diseasedeep brain stimulationmedicine.anatomical_structureSubthalamusTime PerceptionSettore MED/26 - NeurologiaFemalebusinessNeuroscienceNeuroreport
researchProduct

The association of cooking fuels with depression and anxiety symptoms among adults aged ≥65 years from low- and middle-income countries

2022

Background: We aimed to investigate associations of unclean cooking fuels with depression and anxiety symptoms in a large sample of adults aged ≥65 years from six low- and middle-income countries (LMICs). Methods: Cross-sectional, community-based, nationally representative data from the WHO Study on global AGEing and adult health (SAGE) were analyzed. Unclean cooking fuel referred to kerosene/paraffin, coal/charcoal, wood, agriculture/crop, animal dung, and shrubs/grass. Depression referred to DSM-IV depression based on past 12-month symptoms or receiving depression treatment in the last 12 months. Anxiety symptoms referred to severe/extreme problems with worry or anxiety in the past 30 day…

MaleDepressionDepression; Low- and middle-income countriesAnxietyCooking fuelAnxiety Cooking fuel Depression Low- and middle-income countries Mental health Older adults Sustainable goal 7Psychiatry and Mental healthClinical PsychologySustainable goal 7Cross-Sectional StudiesAir Pollution IndoorOlder adultsHumansFemaleMental healthCookingDeveloping Countries
researchProduct

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately …

2017

Background The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone fails to achieve adequate glycaemic control is debated. We aimed to compare the long-term effects of pioglitazone versus sulfonylureas, given in addition to metformin, on cardiovascular events in patients with type 2 diabetes. Methods TOSCA.IT was a multicentre, randomised, pragmatic clinical trial, in which patients aged 50–75 years with type 2 diabetes inadequately controlled with metformin monotherapy (2–3 g per day) were recruited from 57 diabetes clinics in Italy. Patients were randomly assigned (1:1), by permuted blocks randomisation (block size 10), stratified by site and…

MaleDiabetes and Metabolism ipoglycemic drugs cardiovascualr eventSettore MED/09 - Medicina Internaendocrine system diseasesIMPACTpioglitazone versus sulfonylureasEndocrinology Diabetes and MetabolismGLIMEPIRIDEDiabetes cardiovascular events metformin pioglitazone sulphonylureasType 2 diabetes030204 cardiovascular system & hematologyInternal Medicine; Endocrinology Diabetes and Metabolism; Endocrinologylaw.inventionSettore MED/13 - EndocrinologiaGlibenclamide0302 clinical medicineRandomized controlled triallawGLYCEMIC CONTROLGliclazideInternal medicinediabetes and metabolismRISKeducation.field_of_studydiabetesIncidenceInternal medicine; endocrinology diabetes and metabolism; endocrinologyMiddle AgedINSULINMetforminMetforminTreatment OutcomeEditorialsulphonylureasCardiovascular DiseasesCombinationDrug Therapy CombinationFemaleType 2medicine.drugmedicine.medical_specialtyPopulation030209 endocrinology & metabolismAged; Cardiovascular Diseases; Diabetes Mellitus Type 2; Drug Therapy Combination; Female; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment OutcomeCardiovascular events03 medical and health sciencesendocrinologyGLUCOSE-LOWERING DRUGSDrug TherapyInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentssulfonylureaseducationTOSCA.ITAgedPioglitazonebusiness.industryMORTALITYnutritional and metabolic diseasesInsulin resistancemedicine.diseaseSurgeryGlimepirideSulfonylurea CompoundsDiabetes Mellitus Type 2Diabetes Mellitus; Pioglitazone; Insulin resistanceThiazolidinedionesbusinessFOLLOW-UPPioglitazone
researchProduct

Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach?

2021

[Objective] The full phenotypic expression of non-alcoholic fatty liver disease (NAFLD) in lean subjects is incompletely characterised. We aimed to investigate prevalence, characteristics and long-term prognosis of Caucasian lean subjects with NAFLD.

MaleDiseaseBody Mass IndexCohort StudiesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseAdult Body Mass Index Cohort Studies Fatty liver Female Humans Male Middle Aged Non-alcoholic Fatty Liver Disease Non-alcoholic steatohepatitis Prognosis Survival Rate Thinness Whitesnonalcoholic steatohepatitis2. Zero hunger0303 health sciencesFatty liverNASHGastroenterologyMiddle AgedPrognosis3. Good healthSurvival RateCohort030211 gastroenterology & hepatologyFemalemedicine.symptomAdultmedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIAdigestive systemWhite People03 medical and health sciencesThinnessNAFLDInternal medicinemedicineHumansPNPLA3030304 developmental biologyfatty liverbusiness.industryWhitesSettore MED/09 - MEDICINA INTERNAnutritional and metabolic diseasesmedicine.diseaseLean-NASHObesitydigestive system diseasesLean-OutcomesSteatohepatitisbusinessWeight gainBody mass index
researchProduct